Second-line systemic treatment for advanced cholangiocarcinoma

BACKGROUND: Gemcitabine plus platinum (GEM-P) combination chemotherapy is standard treatment for first-line advanced cholangiocarcinoma (aCC). GEM-P first-line therapy reports a progression-free survival (PFS) of 8 months and overall survival (OS) of 11.7 months. Treatment in the second-line setting...

詳細記述

保存先:
書誌詳細
出版年:J Gastrointest Oncol
主要な著者: Rogers, Jane E., Law, Lindsey, Nguyen, Van D., Qiao, Wei, Javle, Milind M., Kaseb, Ahmed, Shroff, Rachna T.
フォーマット: Artigo
言語:Inglês
出版事項: Pioneer Bioscience Publishing Company 2014
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4226829/
https://ncbi.nlm.nih.gov/pubmed/25436118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2014.072
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料